| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. | Chief Executive Officer and Director, Director | Common Stock | 1,190,999 | 04 Feb 2026 | Direct | ||
| Eikon Therapeutics, Inc. | Chief Executive Officer and Director, Director | Common Stock | 284,857 | 06 Feb 2026 | Indirect | ||
| Eikon Therapeutics, Inc. | Chief Executive Officer and Director, Director | Series A-1 Preferred Stock | 0 | 06 Feb 2026 | Indirect | ||
| Eikon Therapeutics, Inc. | Chief Executive Officer and Director, Director | Series D Preferred Stock | 0 | 06 Feb 2026 | Indirect | ||
| NGM BIOPHARMACEUTICALS INC | Director | Stock Option (Right to Buy) | 0 | 05 Apr 2024 | Direct |